Baytril Antibacterial Film Coated Tablets

MFR

Bayer Animal Health

Skip to the end of the images gallery

Refer Friends

Skip to the beginning of the images gallery

Be the first to review this product

SKU

123271

$124.99

Size

Size	Sku	Price	Qty Each	Shipping
		- +

Qty

Wish List Compare

Information

Baytril (enrofloxacin) Antibacterial Tabs are indicated for the management of diseases associated with bacteria susceptible to enrofloxacin. For use in dogs and cats only. Tablets have a non-palatable enteric coating. DOGS: Dermal infections (wounds and abscesses) associated with susceptible strains of Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Staphylococcus intermedius; respiratory infections (pneumonia, tonsillitis, rhinitis) associated with susceptible strains of Escherichia coli and Staphylococcus aureus; and urinary cystitis associated with susceptible strains of Escherichia coli, Proteus mirabilis, and Staphylococcus aureus. CATS: Dermal infections (wounds and abscesses) associated with susceptible strains of Pasteurella multocida, Staphylococcus aureus, and Staphylococcus epidermidis. Federal law prohibits the extralabel use of this drug in food-producing animals.

Directions

More Information

Directions

Dogs:

Administer orally at a rate to provide 5-20 (2.27 to 9.07 mg/lb) of body weight. Selection of a dose within the range should be based on clinical experience, the severity of disease, and susceptibility of the pathogen. Animals which receive doses in the upper-end of the dose range should be carefully monitored for clinical signs that may include inappetance, depression, and vomition.

WEIGHT OF DOG	ONCE DAILY DOSING CHART
	5.0 MG/KG	10.0 MG/KG	15.0 MG/KG	20.0 MG/KG
9.1 kg (20 lb)	2 x 22.7 mg tablets	1 x 22.7 mg plus 1 x 68 mg tablets	1 x 136 mg tablet	1 x 136 mg plus 2 x 22.7 mg tablets

All tablet sizes are double scored for accurate dosing.

Cats:

Administer orally at 5 mg/kg (2.27 mg/lb) of body weight. The dose for dogs and cats may be administered either as a single daily dose or divided into two (2) equal daily doses administered at twelve (12) hour intervals. The dose should be continued for at least 2-3 days beyond cessation of clinical signs, to a maximum of 30 days.